Takeda Pharmaceutical Company Limited (TAK)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 13.08 |
| Open | 13.10 |
| Bid | 13.24 x 1000 |
| Ask | 13.21 x 4000 |
| Day's range | 13.08 - 13.28 |
| 52-week range | 13.01 - 17.11 |
| Volume | |
| Avg. volume | 1,705,726 |
| Market cap | 41.388B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 36.64 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.64 (4.84%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | N/A |
- Zacks
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Zacks
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Zacks
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
© 2024 Yahoo. All rights reserved.